Ennio Lubrano
Overview
Explore the profile of Ennio Lubrano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
201
Citations
2220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrotta F, Antenucci M, Zappia M, Lubrano E
Musculoskeletal Care
. 2025 Feb;
23(1):e70063.
PMID: 39909721
Aim: The aim of the study was to evaluate the ultrasonographic (United States) alterations of the median nerve, the performance of the Kamath screening questionnaire and the clinical examination (Tinel...
2.
Cacciapaglia F, De Angelis R, Ferri C, Bajocchi G, Bellando-Randone S, Bruni C, et al.
J Rheumatol
. 2025 Jan;
PMID: 39814435
Objective: Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU...
3.
Perrotta F, Ambrosino P, Lubrano E
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768461
: In the era of biotechnological drugs, methotrexate (MTX) still represents the first-line treatment in chronic inflammatory arthritis, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and undifferentiated arthritis (UA)....
4.
Falsetti P, Baldi C, Conticini E, Trovato E, Al Khayyat S, Perrotta F, et al.
ARP Rheumatol
. 2025 Jan;
3(4):277-287.
PMID: 39754729
Aims: ultrasound (US) diagnosis of enthesitis is burdened of low specificity, especially when it is performed in patients with psoriasis (PsO) but without clinical psoriatic arthritis (PsA), because of mechanical,...
5.
Lopez-Medina C, Gorlier C, Orbai A, Coates L, Kiltz U, Leung Y, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39752329
Objectives: To explore thresholds for the Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score against disease activity measures in an observational setting, in patients with PsA. Methods: The baseline...
6.
Lubrano E, Mandato F, Antenucci M, Perrotta F
Rheumatol Ther
. 2024 Dec;
12(1):203-209.
PMID: 39638968
Introduction: An intriguing aspect that emerged in recent years is the transition phase from psoriasis (PsO) to psoriatic arthritis (PsA). The PRESTO instrument allows estimating a patient's risk of developing...
7.
Poddubnyy D, Parikh B, Elewaut D, Navarro-Compan V, Siebert S, Paley M, et al.
Arthritis Rheumatol
. 2024 Dec;
PMID: 39624020
Objective: To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with upadacitinib 15 mg. Methods: Data (cutoff: August 15, 2022)...
8.
Lubrano E, Lubrano E, Armuzzi A, Armuzzi A, Scriffignano S, Scriffignano S, et al.
Reumatismo
. 2024 Nov;
PMID: 39526478
Objective: To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD). Methods: An exhaustive literature search was...
9.
Kristensen L, Ng K, Ngantcha M, Morel J, Lubrano E, Tillett W, et al.
RMD Open
. 2024 Sep;
10(3).
PMID: 39306343
Background: The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an interleukin (IL)-17A inhibitor (i) (IL-17Ai), approved...
10.
Ramonda R, Lorenzin M, Chimenti M, DAngelo S, Marchesoni A, Selmi C, et al.
Front Immunol
. 2024 Jul;
15():1435599.
PMID: 39076975
Objectives: This study aims to evaluate in a real-life Italian multicenter cohort of axial spondyloarthritis (axSpA) (1) the 4-year effectiveness and safety of secukinumab, (2) the drug retention rate (DRR),...